Where do Relay Therapeutics, Inc.'s ratios come from?

Every ratio is computed from Relay Therapeutics, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.

	Q1 '26	Q4 '25	Q3 '25	Q2 '25	Q1 '25
Profitability
Operating margin	-2,776.6%+2,002pp	-1,971.5%+1,751pp	-3,914.4%-120pp	-4,105.6%-3,092pp	-4,778.9%-3,754pp
Net margin	-2,554.1%+1,787pp	-1,800.5%+1,574pp	-3,561.4%-112pp	-3,728.4%-2,812pp	-4,341.5%-3,410pp
EBITDA margin	-2,749.9%+1,960pp	-1,948.3%+1,719pp	-3,863%-124pp	-4,046.8%-3,049pp	-4,710.2%-3,700pp
Returns
Return on equity	-40%+5.4pp	-41.1%+3.0pp	-41.1%+1.5pp	-46.2%-3.0pp	-45.5%-5.1pp
Return on assets	-36.4%+4.3pp	-37%+2.3pp	-37.2%+0.4pp	-41.5%-4.3pp	-40.6%-5.6pp
Return on invested capital	-51.8%+3.8pp	-49.7%+4.9pp	-50.9%+2.7pp	-57.9%-3.8pp	-55.6%-4.7pp
Efficiency
Asset turnover	0×0.0×	0×0.0×	0×0.0×	0×0.0×	0×0.0×
Liquidity
Current ratio	22.1×+2.2×	22.6×+6.7×	19.1×+0.7×	20.9×+5.3×	20×-0.8×
Quick ratio	22.1×+2.2×	22.6×+6.7×	19.1×+0.7×	20.9×+5.3×	20×-0.8×
Cash ratio	6.9×+4.4×	3.3×+0.8×	2.8×-0.4×	3.5×+0.5×	2.5×-1.6×
Leverage
Debt-to-equity	0×0.0×	0.1×0.0×	0.1×0.0×	0.1×0.0×	0.1×0.0×
Debt-to-assets	0×0.0×	0.1×0.0×	0×0.0×	0×0.0×	0.1×0.0×
Valuation
Market capitalization	$1.78B+300%	$1.47B+113%	$899.99M-4.3%	$567.48M-33.5%	$444.15M-56.3%
Enterprise value	$1.61B+304%	$1.41B+130%	$841.75M+0.5%	$487.72M-36.7%	$397.76M-56.6%
Price / sales	166.6×+109×	95.5×+26.6×	107.7×+13.7×	67.9×+43.7×	57.8×+29.0×
Price / book	2.8×+2.2×	2.6×+1.7×	1.5×+0.4×	0.9×-0.4×	0.6×-0.7×
EV / sales	150.4×+98.6×	92.1×+30.8×	100.7×+17.0×	58.4×+36.5×	51.8×+25.8×
Earnings yield	-15.3%+59.7pp	-18.9%+30.1pp	-33.1%+3.6pp	-54.9%-17.1pp	-75.1%-42.7pp

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where do Relay Therapeutics, Inc.'s ratios come from?: Every ratio is computed from Relay Therapeutics, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.